Top 20 Venture Capital Firms

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Genetic Engineering and Biotechnology News (12/18/12)

"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?"

In order to start up a company, one must have capital, and for some companies, a venture capital firm may be the best source for it. Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies? Below is a list of top venture capital firms and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active "committed" capital from funds in use.

Genetic Engineering and Biotechnology News

Q1/25 Financials of Cancer Drug Developer Released
Source: Dr. Douglas Loe (06/12/2025)

Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.

Analyst Likes Co. Developing Immuno-oncology Drugs
Source: Dr. Matthew Keller (06/10/2025)

There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report.

New RA Drug Shown to Work, Be Safe
Source: Dr. Martin Fan (06/10/2025)

"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report.

Biotech Firm Unveils Diabetes Breakthrough in Canada
Source: Streetwise Reports (06/10/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.